…………………….catching up on recent FDA approvals The FDA recently approved a new Sub-q therapy, Yorvipath (palopegteriparatide, developed as TransCon PTH) from Ascendis Pharma, to treat hypoparathyroidism in
……………..catching up on recent FDA approvals The FDA recently approved a new therapy, Kisunla (donanemab-azbt) from Eli Lilly and Company, indicated for the treatment of
So, you think you know everything about RARE DISEASES and how inexorably linked pharmacy, specifically specialty pharmacy, is to treatment development? Can you pass the
………….. catching up on FDA Approvals Here’s what we wrote back in July….. The FDA recently approved a biosimilar….. big news…… huh? But wait….. on the same
PBMs have been increasingly under the regulatory microscope for some time…. and recent focus has never been more intense. The pushback from the industry has also
…………catching up on FDA approvals The FDA has approved a new therapy, Pyzchiva (ustekinumab-ttwe) from Samsung Bioepis, as a biosimilar to Janssen Biotech’s Stelara. Pyzchiva is
Artificial Intelligence (AI) is one of the leading topics in media today. But, for many people AI is about as easy to explain as Crypto Currency.
Earlier this week we sent a Report on Walmart opening twenty-five specialty pharmacies. That was about organic growth. Today we are reporting on the changing hands
……….. catching up on FDA Approvals The FDA recently approved a new therapy, Ohtuvayre (ensifentrine) from Verona Pharma plc, for the maintenance treatment of chronic obstructive
……….catching up on FDA approvals We usually don’t report on expanded indications for a therapy previously approved by the FDA. This time one such approval
